Turunen M P, Hiltunen M O, Ylä-Herttuala S
A. I. Virtanen Institute, University of Kuopio, Kuopio, Finland.
Exp Gerontol. 1999 Jul;34(4):567-74. doi: 10.1016/s0531-5565(99)00028-5.
Gene therapy may be useful for the treatment of atherosclerosis and related diseases. Gene transfer to vascular system can be performed both via intravascular and extravascular routes. Gene transfer to other tissues, such as liver and muscle, can also be used. The first clinical trials for the induction of therapeutic angiogenesis with VEGF gene transfer are under way, and preliminary results are promising. In the prevention of restenosis genes inhibiting cellular proliferation and increasing NO production, such as NOS and VEGF, have been used. However, more basic research is needed to fully understand pathophysiological mechanisms involved in conditions related to atherosclerosis. Also, further developments in gene transfer vectors and gene delivery techniques are required for the improvement of the efficacy of gene therapy.
基因治疗可能对动脉粥样硬化及相关疾病的治疗有用。基因向血管系统的转移可通过血管内和血管外途径进行。基因向其他组织(如肝脏和肌肉)的转移也可被采用。用血管内皮生长因子(VEGF)基因转移诱导治疗性血管生成的首批临床试验正在进行中,初步结果很有前景。在预防再狭窄方面,已使用了抑制细胞增殖和增加一氧化氮(NO)生成的基因,如一氧化氮合酶(NOS)和VEGF。然而,需要更多的基础研究来充分了解与动脉粥样硬化相关病症所涉及的病理生理机制。此外,为提高基因治疗的疗效,基因转移载体和基因递送技术也需要进一步发展。